The Global upcoming Mastitis Market trends expected to register a CAGR of 15.07% to reach USD 18,338.80 Million till 2023. Mastitis is an infection in the tissue of one or both mammary glands inside the breast. It usually affects women who are breastfeeding, and it results from a blocked or a plugged duct. In bovine, mastitis is the inflammation of the mammary gland and udder tissue due to bacterial invasion of the teat canal by a variety of bacterial sources present on the farm, and can also occur as a result of chemical, mechanical, or thermal injury to the cow's udder.
The rising cases of breast cancer, increasing rate of pregnancy, and unhygienic barn conditions causing contagious mastitis in bovines across the globe is expected to enhance the market growth. However, the lack of awareness and complications in diagnosis due to similar symptoms of breast cancer & mastitis are projected to curb the growth of the market.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5379
Regional Analysis
The Americas mastitis market is expected to show extensive growth owing to increasing number of patient population for mastitis, and technological advancement in the healthcare. Moreover, high health care spending and increasing government support for research & development are expected to boost the market growth.
Europe holds the second largest share of the global market. The increasing focus of various government agencies on treating mastitis, and increasing investment in healthcare domain to improve treatment methods of rare diseases will fuel the growth of the market. The growing public awareness will boost the European market.
The Asia Pacific is the fastest growing mastitis market across the globe. Japan holds the major share of the regional market due to the availability of technology and huge healthcare spending. Rapidly developing the economy, increasing healthcare expenditure, and government initiatives for research & development are projected to drive the market in China and India over the assessment period. Alongside, there is a huge growth outlook for the market in the developing countries as these countries are encouraging research and development in healthcare management.
The Middle East and Africa hold the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market whereas, the African region is expected to witness a moderate growth.
Segmentation
The global mastitis market is segmented on the basis of types, diagnosis, treatment, and end-users. Based on the types, the market is segmented into contagious mastitis and environmental mastitis. On the basis of the diagnosis, the market is segmented into the physical examination and others. On the basis of the treatment, the market is segmented into antibiotics, pain relievers, surgery, and others. The pain relievers are further segmented into acetaminophen, ibuprofen, and others. Moreover, the acetaminophen is segmented into Tylenol and others. Ibuprofen is further segmented into Advil, Motrin IB, and others. On the basis of the end users, the market is segmented into hospital & clinics, research centers, and others.
Key Players
Some of key the players in the market are Pfizer (U.S.), Novartis AG (Switzerland), Oncogenex (U.S.), Apthera Inc (U.K), BioNumerik Pharmaceuticals (U.S.), Oncothyreon Inc (US), Astellas (Japan), Bipar Sciences (U.S.), Puma Biotechnology (U.S.), Sanofi S.A. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (U.K), Genentech (U.S), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (U.S.), and others.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mastitis-market-5379
No comments:
Post a Comment